NCT01391325

Allopurinol Outcome Study

Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,735 (actual)
• Sponsor: Ardea Biosciences, Inc. · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.

Conditions

• Gout

Interventions

Type	Name	Description
DRUG	Allopurinol	Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.

Timeline

• Start date: 2011-07-01
• Primary completion: 2013-01-01
• Completion: 2013-03-01
• First posted: 2011-07-12
• Last updated: 2014-06-17
• Results posted: 2014-06-17

Locations

173 sites across 7 countries: United States, Australia, Belgium, Canada, Germany, New Zealand, South Africa